Stockreport

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

AstraZeneca PLC Ordinary Shares  (AZN) 
Last astrazeneca plc ordinary shares earnings: 2/5 04:00 pm Check Earnings Report
US:NYSE Investor Relations: astrazeneca.com/investor-relations.html
PDF First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III [Read more]